Botulism MRI

Jump to navigation Jump to search

Botulism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Botulism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Botulism MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Botulism MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Botulism MRI

CDC on Botulism MRI

Botulism MRI in the news

Blogs on Botulism MRI

Directions to Hospitals Treating Botulism

Risk calculators and risk factors for Botulism MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Keanu Ngo[2]

Overview

There are no magnetic resonance imaging (MRI) findings diagnostic of or specific to botulism, because the neurotoxin acts at the peripheral presynaptic neuromuscular junction and is too large to cross the blood–brain barrier; the brain and brainstem are structurally normal and the sensorium remains intact.[1][2] MRI is therefore used not to confirm botulism but to exclude brainstem and posterior-fossa mimics—particularly pontine infarction, hemorrhage, Bickerstaff brainstem encephalitis, and inflammatory or neoplastic brainstem lesions—that can produce overlapping cranial-nerve and bulbar findings. A normal MRI is the expected result and supports, rather than refutes, the diagnosis.[3][4]

MRI scan

There are no MRI findings diagnostic of or specific to botulism. Results of brain imaging are characteristically normal; in the CDC series of 332 U.S. cases (>12 months of age), neuroimaging showed no acute changes in 82% of patients.[3] The AAP Red Book notes that brain imaging may help to exclude strokes or some inflammatory conditions.[5]

The role of MRI is exclusionary, and MRI is the preferred modality for the brainstem and posterior fossa:

  • In acute cranial-nerve dysfunction with descending weakness, the recommended pathway is non-contrast head CT first (to exclude hemorrhage and large territorial stroke), followed by MRI (time permitting) to evaluate brainstem pathology.[4]
  • MRI allows direct, high-resolution assessment of the brainstem and lower cranial nerves. Diffusion-weighted imaging (DWI) is used to detect acute brainstem infarction; thin-cut or coronal DWI improves sensitivity for small infarcts that standard axial DWI may miss.[6]
  • A recommended protocol for suspected inflammatory brainstem lesions includes volumetric FLAIR, T1 with and without gadolinium, T2, DWI, ADC, and SWI sequences.[7]

When MRI is abnormal, the pattern points to a structural mimic rather than botulism:

  • Bickerstaff brainstem encephalitis (a GQ1b-antibody–spectrum disorder overlapping Miller Fisher/GBS) shows T2 prolongation in the posterior pons, often extending around the fourth ventricle, with albuminocytologic dissociation on CSF.[8]
  • Ischemic stroke shows DWI restriction in a vascular territory; inflammatory, infectious, and neoplastic lesions show characteristic T2/FLAIR hyperintensity and enhancement patterns.[9]

Diagnosis remains clinical, confirmed by toxin/organism detection and supported by electrodiagnostic testing; imaging is adjunctive and must never delay antitoxin when botulism is clinically suspected.[5][10]

References

  1. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  2. ↑ Liu SC; Poon JT; Candee MS (2021). "Clinical Reasoning: A Teenager With Shortness of Breath and Difficulty Walking". Neurology.
  3. ↑ 3.0 3.1 Rao AK; Lin NH; Jackson KA; Mody RK; Griffin PM (2017). "Clinical Characteristics and Ancillary Test Results Among Patients With Botulism—United States, 2002-2015". Clinical Infectious Diseases. PMID 29293936.
  4. ↑ 4.0 4.1 Schreck KC; Schneider L; Geocadin RG (2015). "Clinical Reasoning: A 44-Year-Old Woman With Rapidly Progressive Weakness and Ophthalmoplegia". Neurology.
  5. ↑ 5.0 5.1 American Academy of Pediatrics (2024). Botulism and Infant Botulism (Clostridium botulinum). Red Book: 2024–2027 Report of the Committee on Infectious Diseases.
  6. ↑ Expert Panel on Neurological Imaging; Rath TJ; Policeni B; et al. (2022). "ACR Appropriateness Criteria Cranial Neuropathy: 2022 Update". Journal of the American College of Radiology.
  7. ↑ Law LY; Riminton DS; Nguyen M; et al. (2019). "The Spectrum of Immune-Mediated and Inflammatory Lesions of the Brainstem: Clues to Diagnosis". Neurology.
  8. ↑ Sarma A; Heck JM; Bhatia A; Krishnasarma RS; Pruthi S (2021). "Magnetic resonance imaging of the brainstem in children, part 2: acquired pathology of the pediatric brainstem". Pediatric Radiology.
  9. ↑ Rock M; Shipley SC; Little JN; Berger JR; Xu DJ (2025). "Clinical Reasoning: A 60-Year-Old Man With Rapidly Progressive Left Hemibody Weakness and Vision Loss". Neurology.
  10. ↑ Kuehn BM (2021). "Botulism Guidelines Aim to Help Prepare Clinicians for Outbreaks". JAMA. 325 (24): 2428. doi:10.1001/jama.2021.8969.


Template:WikiDoc Sources